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| INTRODUCTION
The direct thrombin inhibitor dabigatran has been the first direct oral anticoagulant (DOAC) approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for prevention or treatment of venous thromboembolism.
1 Although dabigatran was developed for fixed-dose administration in patients with standard conditions without the need of routine laboratory monitoring and dose adjustment, there is now the widespread awareness that some clinical situations, such as adverse (thrombotic/hemorrhagic) This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
events or emergency invasive procedures and others, might require the measurement of the drug plasma levels. 2, 3 The global coagulation test activated partial thromboplastin time (aPTT) was initially indicated as the method to measure the degree of anticoagulation in patients treated with dabigatran due to its wide availability and low cost. However, recent studies showed that aPTT has a low sensitivity to dabigatran levels and different responsiveness depending on commercial reagents. Furthermore, normal results
are not always associated with the absence or minimal residual concentration of the drug. 4, 5 Over the last years, several manufacturers developed specific functional tests for dabigatran plasma levels assessment, including thrombin-based clotting assays and ecarin clotting time or chromogenic assays. These methods showed good agreement with liquid chromatography-tandem mass spectrometry (LC-MS/MS) that is considered as the gold standard. 6, 7 Accordingly, the most recent guidelines of the British Committee for Standards in Haematology (BCSH) and the guidelines of the International Society on Thrombosis and Haemostasis (ISTH) recommended the use of dedicated assays calibrated with drug-specific calibrators, and stated that aPTT should not be used to determine dabigatran plasma concentration. 3, 8 Aim of this study was to evaluate five commercially available specific assays for the measurement of dabigatran in plasma from a relatively large number of patients taking dabigatran. We also investigated assay's performances in the low dabigatran concentration range. 
| MATERIALS AND METHODS

| Patients
| Assays for dabigatran measurement
Dabigatran anticoagulant activity, expressed as drug concentrationequivalent (ng/mL), was measured by the combination of reagent/ platform/calibrators and controls previously agreed in the study design as reported in Table 1 ; each assay was performed in a single center.
Assays were calibrated in duplicate before the beginning of the study according to manufacturer's indications using reference lyophilized standards; calibration ranges and equations of calibration curves are described in Table S1 . For HTI-HY assay, manufacturers also provided low calibrators, and the calibration curve in the low range was set up in duplicate (HTI-HY low range curve); results <50 ng/mL with HTI-HY were repeated using the low range protocol, as indicated by the manufacturer. For all methods, results higher than the upper end of the calibration curve were diluted and retested.
On each working session, quality control (QC) samples were tested in single determination before the patient samples; if they fell out of the acceptance range, a new calibration curve was carried out. Tested samples were checked for hemolysis, clots, or lipemia.
| Statistical analysis
Data are presented as mean and standard deviation (SD) or median and range (min-max); coefficient of variation (CV%) was calculated as (SD/mean) × 100. Accuracy and between-run precision were assessed by measuring drug concentrations for QC levels on consecutive working days. Accuracy was evaluated as follows: accuracy % = (measured concentration of QC sample/target value declared by the manufacturer) × 100. Accuracy was considered acceptable if ranging from 85% to 115%. Precision expressed as CV was acceptable if <15%.
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To estimate the assay's repeatability at dabigatran concentrations near the lower end of the calibration range, two lyophilized dabigatran calibrators (Hyphen BioMed) with declared concentrations of 255 ng/mL and 30 ng/mL and a locally prepared pooled normal plasma were mixed to obtain a set of samples (from A to D) with the following final dabigatran concentrations: 60, 30, 20, and 10 ng/mL. They were run 10 times with each method in the same working day, and the CV was calculated.
The limit of detection (LOD) and the limit of quantification (LOQ)
were evaluated repeating a pooled normal plasma 10 times with each assay. Raw data (expressed as OD/min or seconds) were reported on the X-axis of the calibration curves to obtain Y0 values, and LOD or LOQ was computed as follows: LOD = Y0 + 3SD and LOQ = Y0 + 10SD (for chromogenic assays LOD = Y0−3SD and LOQ = Y0−10SD). 
| RESULTS
| Assay's precision and accuracy
All assays showed acceptable between-run precision and accuracy for the QC levels tested (total CVs from 3.3% to 11.2%; total accuracy from 91% to 111%) ( Table 2) . Table 3 
| Limits of detection (LOD) and quantification (LOQ)
As shown in Table 4 , LOD and LOQ values considerably varied between methods, ranging from 4 to 52 ng/mL and from 7 to 82 ng/mL, respectively. Data lower than LOQ for each assay were excluded from the analysis.
| Evaluation of five assays for dabigatran testing
A total of 254 patients were enrolled in the study by the 4 collaborative clinics. A total of 544 plasma samples (309 trough samples and 235 peak samples) were collected and tested for dabigatran concentration; occasionally, plasma volume was insufficient, and not all methods could be tested. We included in the analysis only samples for which all tests have been performed (295 plasma samples: 140 trough samples and 155 peak samples).
As explained in the Material and Methods section, dabigatran concentrations <50 ng/mL with HTI-HY were repeated using HTI-HY low range protocol. Figure 1 reports the comparison between standard and low range HTI-HY assays, evaluated by Bland-Altman analysis: the mean difference of results was −7.3 ng/mL (P < .0001; 95%
LoA from −21.3 to 6.6 ng/mL), suggesting that HTI-HY low range assay was able to detect lower dabigatran concentrations.
In our analysis, HTI-HY values <50 ng/mL were replaced with corresponding results obtained with HTI-HY low range assay. Trough and peak mean dabigatran concentrations measured with the five methods are in Table 5 . Differences were significant for trough and peak values (P < .0001; P values for Dunn's multiple comparison are shown in Table S2 ).
The agreement between the reference assay (HTI-HY) and other methods was evaluated by the Bland-Altman analysis, where trough and peak values were assessed together ( Figure 2 ). The mean difference of results between HTI-HY and ECA-STA was the closest to 0 ng/mL and not statistically significant (−2.4 ng/mL, P = .19).
The bias between HTI-HY and other assays suggested a modest but Table S3 .
Close scrutiny of the plots showed that the scatter of differences increased for high dabigatran values (approximately above 200 ng/mL). To better evaluate the agreement between methods at different dabigatran concentrations, data were stratified into 3 groups according to HTI-HY results (group 1 < 100 ng/mL; group 2 = 100-200 ng/mL; group 3 > 200 ng/mL), and Bland-Altman analysis was repeated. As shown in Table 6 , ECA-STA confirmed the lowest deviation of results compared to HTI-HY in all subgroups, as indicated by the mean of differences that was very close to 0 ng/mL and not statistically significant, especially for group 2 (bias −0.7 ng/mL) and group 3 (bias 0.6 ng/mL). DTI-IL and DTI-SI slightly overestimated dabigatran concentrations compared to HTI-HY in all groups (bias from −5.0 to −30.9 ng/mL). Results of DTI-TC were slightly higher than HTI-HY at low concentrations (<100 ng/mL, bias = −22.5 ng/mL), and lower in the other groups, especially for >200 ng/mL (bias = 26.2 ng/mL).
The 95% limits of agreement were generally higher for dabigatran concentrations above 200 ng/mL (95% LoA lower end from −122.1 to −41.0 ng/mL and 95% LoA upper end from 58.6 to 104.5 ng/ mL) compared to group 1 (95% LoA lower end from −76.6 to −52.6 ng/mL and 95% LoA upper end from 14.6 to 33.6 ng/mL). Similar results were obtained by Bland-Altman analysis calculated as % differences between HTI-HY and other assays in each subgroup, as reported in Table S4 .
| DISCUSSION
In the era of DOAC, the role of the clinical laboratory for the control of anticoagulation has proved essential in several clinical situations, both for emergency and for the optimal management of the therapy.
Increasing evidences have highlighted limitations of the routine global test aPTT for dabigatran measurement, mostly with some reagents, whereas specific chromogenic or clotting-based assays have proven to be accurate and responsive. In the present study, we evaluated several methods that are currently available from different manufacturers for dabigatran measurement (see Table 1 ). Some are clotting assays (Technoclot DTI Hemoclot for dabigatran concentrations <50 ng/mL proved to be inferior to the gold standard LC-MS/MS, [13] [14] [15] [16] [17] other data showed that the use of specific low calibrators could improve the performance of Hemoclot assay for levels below 50 ng/mL. 6, 7 In our study, dabigatran levels <50 ng/mL were tested by HTI-HY low range protocol that showed better precision and lower LOD and LOQ compared to standard HTI-HY assay. Our results suggested that the agreement between HTI-HY and the other evaluated assays was overall good. The ECA-STA was the test with less systematic difference compared to HTI-HY, also after stratification of dabigatran levels:
deviation of results was very close to 0 ng/mL for each concentration range, as shown by the Bland-Altman analysis (see Figure 2 and Table 6 ). For the other methods, we observed a modest over (DTI-IL and DTI-SI) or under-estimation (DTI-TC); for some the agreement improved in a specific concentration range (eg, in the 100-200 ng/mL range for DTI-IL and DTI-TC or above 200 ng/mL for DTI-SI).
All the evaluated assays showed good between-run precision and accuracy for the QC levels tested (see Table 2 ). The assay's repeatability at the lower end of the calibration range was assessed testing samples with dabigatran concentrations from 10 to 60 ng/mL, and it was acceptable; as expected, assay's variability increased with decreasing dabigatran levels as shown by CVs (see Table 3 ).
The calculated LOD and LOQ were quite different among the evaluated assays: one method allowed accurate detection of very low values (DTI-IL), while others had slightly higher LOD/LOQ (ECA-STA and HTI-HY) or even more (DTI-SI and DTI-TC).
All the methods were easy to set up, fully automated and robust as shown by the validity over time of the calibrations. They also proved suitable to be applied in emergency because results were available within few minutes.
The main limitation of the study is the lack of comparison between specific assays and the gold standard LC-MS/MS; nevertheless, the use of Hemoclot as reference test in our analysis is due to the good correlation of Hemoclot with liquid chromatography reported in literature, as described above. 12 Moreover, in our study, we did not compare results of the same assay performed in different laboratories, as our aim was to evaluate the performance of specific tests removing interlaboratories variability, which has been discussed by other authors. 9 At last, we calculated the mean bias between reference (Hemoclot) and test methods using the average concentrations of reference and test method as "true" concentrations; this approach results in smaller bias than using dabigatran levels determined by Hemoclot as reference. LoA, limits of agreement.
